Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
61 studies found for:    b7-dc
Show Display Options
Rank Status Study
1 Active, not recruiting Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: B7-DC cross-linking antibody rHIgM12B7;   Other: flow cytometry;   Other: immunologic technique;   Other: laboratory biomarker analysis
2 Recruiting AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy in People With Metastatic Colorectal Cancer
Conditions: Colorectal Cancer;   Colorectal Neoplasms;   Colorectal Carcinoma
Interventions: Drug: AMP-224;   Radiation: Stereotactic Body Radiation Therapy(SBRT);   Drug: Cyclophosphamide
3 Suspended Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy
Condition: HIV Infections
Interventions: Drug: BMS-936559;   Drug: Placebo for BMS-936559
4 Recruiting A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)
Condition: Renal Cell Cancer
Interventions: Drug: Pembrolizumab;   Procedure: Surgical Resection
5 Recruiting Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation
Condition: Postoperative Atrial Fibrillation
Interventions: Drug: Amiodarone;   Procedure: DC-cardioversion;   Drug: Rate Control
6 Completed Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells
Conditions: Metastatic Melanoma;   Absence of CNS Metastases
Intervention: Biological: Proteasome siRNA and tumor antigen RNA-transfected dendritic cells
7 Recruiting Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Intervention: Drug: CP-690,550
8 Recruiting Multiple Antigen-Engineered DC Vaccine for Melanoma
Condition: Melanoma
Interventions: Biological: DC Vaccine + IFN;   Biological: AdVTMM2/DC Vaccination
9 Completed
Has Results
A Study to Evaluate the Effectiveness and Safety of MEDI-528 in Adults
Condition: Asthma
Interventions: Biological: MEDI528 30 mg;   Biological: MEDI528 100 mg;   Biological: MEDI528 300 mg;   Other: Placebo
10 Active, not recruiting Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage Phase III
Condition: Intraventricular Hemorrhage
Interventions: Drug: Cathflo Activase;   Other: Normal saline
11 Completed Warfarin and Antiplatelet Therapy in Chronic Heart Failure
Condition: Heart Failure
Interventions: Drug: Warfarin titrated to an INR of 2.5-3.0;   Drug: Aspirin;   Drug: Clopidogrel 75
12 Unknown  Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass
Conditions: Cardio-pulmonary Bypass;   Coronary Artery Bypass Graft
Intervention: Drug: pexelizumab
13 Completed Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell Carcinoma (RCC) Patients
Condition: Metastatic Renal Cell Carcinoma
Interventions: Biological: DC vaccine;   Drug: Bevacizumab;   Biological: IL-2;   Biological: IFN
14 Active, not recruiting A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
Condition: Breast Neoplasms
Interventions: Drug: PD-0332991;   Drug: Letrozole;   Drug: Placebo
15 Completed
Has Results
A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC).
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006);   Drug: Placebo
16 Recruiting Safety Study Of Anakinra Combined With Chemotherapy And Dendritic Cell Vaccine to Treat Breast Cancer
Condition: Breast Cancer
Interventions: Biological: DC vaccination+Preop chemotherapy;   Biological: DC vaccination+Preop chemo+anakinra
17 Recruiting Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: DC vaccine;   Drug: Dasatinib
18 Completed Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma
Condition: Melanoma (Skin)
Intervention: Biological: dendritic cell-MART-1 peptide vaccine
19 Recruiting In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
Condition: Low-Grade B-cell Lymphoma
Interventions: Drug: rhuFlt3L/CDX-301;   Drug: Poly-ICLC
20 Completed Maternal Immunization To Prevent Infant Otitis Media
Condition: Otitis Media
Interventions: Biological: PNCRM9;   Biological: Placebo comparator

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years